TP53 and ovarian cancer: To investigate the reasons for different drug response observed in our freshly generated primary ovarian cancer cells, a p53 mutational study was assessed and we found that two out of the five cell lines tested, carried a homozygous missense mutation at codon 72 in the exon 8 of the p53 gene.